Clinical Trials Logo

Clinical Trial Summary

Populations from Sub-Saharan Africa represent one of the most dynamic immigration flows in France and are among the most exposed to HIV infection and hepatitis B.

The Parcours study aims to understand, among sub-Saharan African migrants, how social and individual factors combine in the course of migration and settlement in France, and influence the risk of infection, access to prevention and care, and the effectiveness of care for both HIV and hepatitis B diseases.

The research was conducted in Ile-de-France, where 60% of sub-Saharan African migrants reside. It consists in a cross-sectional observational survey, using a life-event history approach that reproduces the sequence of different life and health events, and contributes to explain the present situation (type of disease management, patient's quality of life) in light of all the elements of the past trajectory (administrative, familial, socio-economic, professionals).

A representative survey was conducted between February 2012 and May 2013 in health care facilities in Ile-de-France, among three groups of migrants from Sub-Saharan Africa: a group living with HIV, a group living with chronic hepatitis B and a group who has neither of these diseases. For each group, stratified random sampling was used. The survey was conducted in 24 hospital services providing HIV care, 20 health care facilities providing hepatitis B care, and 30 primary health care facilities.

Were eligible all patients attending these health care facilities, born in a Sub-Saharan African country and with Sub-Saharan African citizenship at birth, aged 18 to 59 years, with an HIV diagnosis (HIV group) or chronic hepatitis B diagnosis (hepatitis B group) more than three months prior or not diagnosed with HIV or chronic Hepatitis B (reference group).

Among the patients offered participation, 926 HIV-infected patients, 779 patients infected by hepatitis B, and 763 patients without these two diseases participated in the study.

For all participants, detailed information on socio-demographic characteristics; migration and life conditions in France; social, sexual and reproductive life history; and screening and care history were collected using a life-event history questionnaire administered face-to-face by a specialized interviewer. Health care professionals documented clinical information from the medical records. Data was collected anonymously.


Clinical Trial Description

The PARCOURS study was conducted to study how health trajectories and social and migratory paths are interlaced for migrants from sub-Saharan Africa living in France. This retrospective quantitative life-event survey was conducted from February 2012 to May 2013 in health-care facilities in the greater Paris metropolitan area (Ile-de-France), among three groups of migrants born in sub-Saharan Africa: one group receiving HIV care, one group with chronic hepatitis B, and a third group of people visiting primary-care centres. Recruitment took place at facilities randomly selected from an exhaustive list of HIV outpatient hospital clinics (n=24), hepatitis treatment clinics (n=20) and general practice medical centres (n=30).

Recruitment procedure for patients in each group:

Within each health care facility selected for the study, all health care professionals providing outpatient care to patients born in sub-Saharan Africa were asked to participate in the study. They identified eligible patients during consultations based on medical records, and offered study participation to all eligible patients, except when the patient was deemed unable to be interviewed (for mental health or physical health reasons or because were unable to be interviewed in one of the languages spoken by the interviewer). When the patient agreed to participate in the study, health care professionals gave her/him an information leaflet on the study and obtained written consent. They also gave the participant a card bearing an identification number to ensure data collection anonymity and confidentiality, and referred her/him to the Parcours interviewer at the end of the consultation. The Parcours interviewer conducted the interview right after the consultation, in face-to-face mode, in a dedicated room, with closed door to ensure privacy.

The health care professional could also suggest an appointment in the following days, always on site, to patients who agreed to participate in the study but were not immediately available.

Consideration of non-Francophone participants:

To take into account difficulties in participating in the survey due to poor or no knowledge of the French language, the patient questionnaire was available in French or English, and, by appointment, an interpreter could be made available to conduct the interview in an African language spoken by the respondent.

Type of data collected

Several data collection tools were used:

Information register :

In each service investigated, each health care professional participating in the study held an information register. Each page of the register had two parts, one with a detachable section specifying the correspondence between the identity of study patients and their identity number, and an anonymous one describing the main characteristics of eligible patients. During each consultation day, the health care professional listed in the register all eligible patients, their gender, age group, if the patient had worked at least one day in the previous month, a health indicator (last CD4 count for HIV + patients, last alanine transaminase (ALT) level for patients with hepatitis B, the fact of consulting in this facility for the first time for patients in the reference group), and participation in the survey (participant, not offered participation, refusal).

Life-event history questionnaire

Participants were interviewed using a standardized life-event history questionnaire administered by an interviewer face-to-face (average duration 55 minutes). The life-event questionnaire consisted of two parts:

- A list of questions associated with a life event calendar (or biographical grid), which allowed identifying, recording and dating (per year) events in the lives of the respondents, from birth to the date of the survey, and in the various themes explored in the study.

- A book of thematic modules, aimed at describing in-depth the events previously identified in the biographical grid (or some of them).

The life-event calendar has a very graphic and visual form, which makes it easier to remember, record and date the events in the lives of the respondents. In particular, it encourages and easily adapts to the process of remembering that works by association of ideas and connections between life-event areas and as such optimizes data collection, in terms of completeness and reliability of the data collected.

The themes explored in the life-event questionnaire were:

Gender, age ; Residential biography and housing history ; Place of birth and places of residence. ; Work history - Education and Resources ; Marital and family history ; History of testing ; General health and history of disease ; Arrival in France and stay in France ; Sexual and reproductive health ; Social networks, support networks

Medical questionnaire :

The health care professional completed the medical questionnaire, from the patient's medical record. For the HIV and hepatitis B groups, this questionnaire documented the chronological landmarks and key parameters of the disease and its treatment. For the reference group, it informed the reason for consultation, potential diseases at the time of the survey, and current treatments.

Anonymity of data:

The identity number on the anonymity card given by the health care professional to the patient was the only participant identifier for the different survey questionnaires (thematic book and life-event calendar, medical questionnaire). The interviewer did not know the identity of the patient. No personally identifiable data was collected directly or indirectly for eligible individuals not offered participation or individuals refusing study participation. The general characteristics collected on the register among refusals were collected in the form of classes, and not precisely, thus not allowing for later identification.

Ethical approvals :

The survey was approved by the Advisory Committee for Data Processing in Health Research (CCTIRS) (approval on 13 April 2011) and by the National Commission on Informatics and Liberties (CNIL) (CD-2011-484 approval on 7 December 2011).

Data collection :

Between 30/01/2012 and 31/12/2012, 1,829 individuals infected with HIV and meeting the eligibility criteria presented at the participating services, among which 141 were not offered participation by their physician (111 for health reasons and 30 for language problems). Of the 1,688 individuals offered participation, 762 refused or abandoned during the questionnaire. In total, 926 individuals were included.

Between 15/02/2012 and 31/05/2013, 1,169 individuals infected with hepatitis B and meeting the eligibility criteria presented at the participating services, among which 17 were not offered participation by their physician and 8 abandoned during the questionnaire due to language problems. In total, among the 1,135 individuals offered participation, 779 were included.

Between 15/02/2012 and 31/05/2013, 1,184 meeting the eligibility criteria presented at the participating primary health care facilities. Among these, 124 were not offered participation by their physician (91 for health reasons and 33 for language problems). Among the 1,060 individuals offered participation, 297 refused or abandoned during the questionnaire. In total, 763 individuals were included.

Among all services and groups, the number of refusals due to language problems was 71 (30 in HIV group, 8 in Hepatitis B group and 33 in reference group), to which can be added 10 interviews interrupted due to poor understanding of French (8 in hepatitis B group and 2 in reference group).

Weighting :

In order to take into account the sample design and non-participation, data was weighted according to each individual's probability of inclusion in the survey (i.e. considering the probability of inclusion in the sample for each health care facility, the number of half-days of weekly consultations in each facility included and the individual study participation per half-day of included consultations). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02566148
Study type Observational
Source French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Contact
Status Completed
Phase N/A
Start date February 2012
Completion date May 2013

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02135419 - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions Phase 3
Active, not recruiting NCT02663856 - My Smart Age With HIV: Smartphone Self-assessment of Frailty
Completed NCT02921516 - Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings N/A
Completed NCT02663869 - Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
Completed NCT02846402 - Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda N/A
Terminated NCT02743598 - Liraglutide for HIV-associated Neurocognitive Disorder Phase 4
Completed NCT02659306 - Metformin Immunotherapy in HIV Infection Phase 1
Completed NCT02564341 - Targeting Effective Analgesia in Clinics for HIV - Intervention N/A
Active, not recruiting NCT02302950 - A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas N/A
Terminated NCT01902186 - Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir Phase 4
Terminated NCT02109224 - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection Phase 1
Completed NCT02269605 - Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Phase 1
Completed NCT01852942 - Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV Phase 2
Completed NCT01830595 - Lactoferrin Treatment in HIV Patients Phase 2
Completed NCT02118168 - Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002 N/A
Completed NCT02525146 - Birmingham Access to Care Study N/A
Completed NCT02527135 - Text Messaging to Improve HIV Testing Among Young Women in Kenya N/A
Completed NCT01946217 - Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials N/A
Active, not recruiting NCT02602418 - Neural Correlates of Working Memory Training for HIV Patients N/A
Completed NCT01702974 - Immune Reconstitution in HIV Disease (IREHIV) Phase 2